An open-label, multicenter, phase II study evaluating the safety and efficacy of twice daily dosing of SOM230 [pasireotide] in patients with metastatic carcinoid tumours.

Trial Profile

An open-label, multicenter, phase II study evaluating the safety and efficacy of twice daily dosing of SOM230 [pasireotide] in patients with metastatic carcinoid tumours.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2012

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Carcinoid tumour
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Actual patient number (45) added as reported by ClinicalTrials.gov.
    • 21 Apr 2008 Status changed from in progress to completed, as reported by Novartis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top